{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1258986604", "close" : "1259010004", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
globenewswire

Beacon Equity Issues Technical Trading Overview for VeriChip Corp.

  • Press Release
  • Source: Beacon Equity
  • On 6:50 am EDT, Wednesday September 23, 2009

DALLAS, Sept. 23, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring technology company VeriChip Corp. (Nasdaq:CHIP - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. The investment report on VeriChip Corp. (Nasdaq:CHIP - News) should be of particular interest to other technology companies: AXCESS International Inc. (OTCBB:AXSI - News), Checkpoint Systems Inc. (NYSE:CKP - News) and I.D. Systems Inc. (Nasdaq:IDSY - News).

Related Quotes

SymbolPriceChange
AXSI.OB0.560.00
Chart for AXCESS INTL INC
{"s" : "axsi.ob,chip,ckp,idsy","k" : "c10,l10,p20,t10","o" : "","j" : ""}

It is available at: http://www.beaconequity.com/i/CHIP

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

VeriChip Corp. (CHIP) engages in the development of human-implantable RFID microchip technology for patient identification. The Company's product is the world's first and only human-implantable RFID (radio frequency identification) microchip cleared by the Food and Drug Administration (FDA).

In the report, the analyst notes:

"On June 11, 2009, the WHO raised the threat of the H1N1 to phase 6, a pandemic alert of the highest level. The last time a pandemic outbreak of this severity occurred was in 1968, when the Hong Kong flu caused the death of more than 1 million individuals worldwide. According to the WHO, phase 4 through phase 6 alerts include recommendations to mitigate the spread of the H1N1.

"CHIP is positioned to address some of the challenges and concerns surrounding the spread of the virus; CHIP's implantable RFID chips and patent licenses will be combined with Receptors LLC's biosensors to develop a virus triage detection system. The triage system is expected to provide information identifying whether there is a virus present; classify the virus as a pandemic threat, or not; and identify the pathogen, according to the CHIP white paper of May 7, 2009."

To read the entire report visit: http://www.beaconequity.com/i/CHIP

See what investors are saying about these stocks at: http://www.stockhideout.com/

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Contact:

Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.